Lineage Announces a Grand Prize of $50,000 for the Food Chain Innovation Challenge
5.9.2024 14:31:00 CEST | Business Wire | Press release
The global winner will receive substantial prize from Lineage and invite to a six-month, executive-led incubator program to help kick start their business
Lineage, Inc. (NASDAQ: LINE) (the “Company”), the world’s largest global temperature-controlled warehouse REIT, today announced additional details of its flagship competition, the Food Chain Innovation Challenge, including members of the judging panels as well as the grand prize.
The challenge of creating impactful solutions for food waste comes at a critical time, as the severely food-insecure population is expected to hit nearly a billion people by 2028. Lineage’s global competition invites students and startups to pitch their innovative technologies or data solutions that address postharvest food waste.
The Food Chain Innovation Challenge will take place in three major locations: London on November 14, and Amsterdam and San Francisco both on November 19. Students, startups and other relevant candidates interested in participating can submit their applications online until September 30.
During each event, participants will present solutions aimed at mitigating food waste to an esteemed regional judging panel. Judges will select a regional winner, who will be awarded a $5,000 cash prize and a spot in the grand final event on December 2. One winner will then be chosen to receive the $50,000 grand prize and an invite into a six-month, executive-led incubator program tailored to their unique business goals.
London
The London event will take place on November 14, 2024, at The Science Museum. Lineage’s Regional Vice President, Clare Walters, will join a panel of distinguished judges including Simon Millard, Director of Food at FareShare; Harriet Lamb, CEO of WRAP; and Paul Randle, from the Cambridge Institute for Sustainable Leaders at Cambridge University. To support the aspiring innovators, ReLondon and FoodCycle are also partnering with the Food Chain Innovation Challenge to provide valuable insights and coaching as applicants refine their pitches.
Amsterdam
The Amsterdam event will take place on November 19, 2024, at The NEMO Science Museum. Lineage’s European President, Harld Peters, will join a panel of distinguished judges including Toine Timmermans, Director of Samen Tegen Voedselverspilling; Enno Masurel, Professor Doctor of Sustainable Entrepreneurship at the Free University Amsterdam; and Esteban Arriaga, CEO of FEBA (European Food Banks Federation).
San Francisco
The San Francisco event will take place on November 19, 2024, at the California Academy of Sciences. Lineage’s Global Chief Operations Officer Jeff Rivera will join a panel of distinguished judges, including Angel Veza, Capital, Innovation, & Engagement Senior Manager at ReFED; Danielle Todd, Founder and Executive Director at Make Food Not Waste; and Michael Wara, Director, Climate and Energy Policy Initiative at Stanford's Woods Institute for the Environment and Senior Director, Policy at the Sustainability Accelerator within the Stanford Doerr School of Sustainability.
Greg Lehmkuhl, President and CEO of Lineage, said: “Lineage is constantly looking at how we improve the global management of food storage, transportation and distribution. Beyond our own operational improvements, the Food Chain Innovation Challenge is a platform for us to support the industry's most promising talent and innovations. By collaborating, we can develop solutions that not only address food waste but also promote sustainable practices for the long term.”
Jeff Rivera, Global Chief Operations Officer at Lineage, added: “Despite producing enough food to feed the planet, hundreds of millions of people face food insecurity every day. At Lineage, we're dedicated to transforming the food supply chain to eliminate waste and feed the world. The Food Chain Innovation Challenge exemplifies this mission, and we’re excited to highlight new solutions and innovations while supporting these entrepreneurs' journeys to turn their ideas into reality.”
At the events, participants will be asked to pitch their existing ideas across four specific areas: reducing food waste, food preservation techniques, access to nutritious food and data-driven insights and analytics.
If you're interested in participating, apply here. For a glimpse into the 2023 Hackathon, the predecessor to The Food Chain Innovation Challenge held in Amsterdam, watch this video. Also, hear insights from last year's winner to get inspired and understand the impact of winning this prestigious challenge.
About Lineage
Lineage, Inc. (NASDAQ: LINE) is the world’s largest global temperature-controlled warehouse REIT with a network of over 480 strategically located facilities totaling over 84 million square feet and approximately 3.0 billion cubic feet of capacity across countries in North America, Europe, and Asia-Pacific. Coupling end-to-end supply chain solutions and technology, Lineage partners with some of the world’s largest food and beverage producers, retailers, and distributors to help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, feed the world. Learn more at onelineage.com and join us on LinkedIn, Facebook, Instagram, and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905272650/en/
Contacts
Media Contact
Media Contact
Christina Wiese
Public Relations Manager
cwiese@onelineage.com
734-608-1855
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom